Search

Displaying results 5821 - 5830 of 10000 in total
  1. Drug

    D2C7 immunotoxin

    go.drugbank.com/drugs/DB17540
    Investigational

    D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the _Pseudomonas exotoxin_, PE38-KDEL.

  2. Drug

    AVR-RD-05

    go.drugbank.com/drugs/DB18631
    Experimental

    AVR-RD-05 is a gene therapy comprising genetically modified autologous stem cells transduced _ex vivo_ with a lentiviral vector encoding the human iduronate-2-sulfatase (IDS) enzyme.

    Synonyms: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
  3. Drug

    Farletuzumab ecteribulin

    go.drugbank.com/drugs/DB18857
    Investigational

    Farletuzumab ecteribulin is under investigation in clinical trial NCT04300556 (A Study to Evaluate the Safety, Tolerability, and Efficacy of Morab-202 (Herein Referred to as Farletuzumab Ecteribulin), … a Folate Receptor Alpha (Frα)-targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types).

  4. Drug

    5-(5-(4-(4,5-dihydro-2-oxazoly)phenoxy)pentyl)-3-methyl osoxazole

    go.drugbank.com/drugs/DB08720
    Experimental

    These are aromatic compounds containing an ether group substituted with a benzene ring. This drug is known to target genome polyprotein. … 5-(5-(4-(4,5-dihydro-2-oxazoly)phenoxy)pentyl)-3-methyl osoxazole is a solid. This compound belongs to the phenol ethers.

  5. Drug

    OTL-201

    go.drugbank.com/drugs/DB17652
    Experimental

    It consists of a lentiviral vector to insert a functional copy of the human N-Sulfoglucosamine Sulfohydrolase (SGSH) gene into autologous CD34+ hematopoietic stem cells.[L45973] … OTL-201 is an investigational hematopoietic stem cell (HSC) gene therapy being developed by Orchard Therapeutics for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA).

  6. Drug

    TD-2749

    go.drugbank.com/drugs/DB05905
    Experimental

    such as chronic constipation, constipation-predominant irritable bowel syndrome (C-IBS), opioid-induced constipation, functional dyspepsia and diabetic gastroparesis. … TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders

  7. Drug

    OBE101

    go.drugbank.com/drugs/DB05080
    Experimental

    OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine. … Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management indications.

  8. Drug

    Androstenediol

    go.drugbank.com/drugs/DB01524
    ExperimentalIllicit

    Androstenediol is an intermediate in [testosterone] biosynthesis, found in the testis or the adrenal glands. … Androstenediol, derived from dehydroepiandrosterone by the reduction of the 17-keto group (17-hydroxysteroid dehydrogenases), is converted to testosterone by the oxidation of the 3-beta hydroxyl group to a

  9. Drug

    Ginsenoside Rb1

    go.drugbank.com/drugs/DB06749
    ExperimentalNutraceutical

    Ginsenosides have been the target of research, as they are viewed as the active compounds behind the claims of ginseng's efficacy. … Ginsenosides are a class of steroid glycosides, and triterpene saponins, found exclusively in the plant genus Panax (ginseng).

  10. Drug

    Lumicitabine

    go.drugbank.com/drugs/DB14808
    Investigational

    Lumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and